Table 7.

Summary of the publications included in this review that report differential responses to “other” medications.

Author(s)	Study Description	Drug(s)	Sequencing Method	Outcome	Association	Odds Ratio/95% Confidence Intervals/p-value
Di Lorenzo et al. (2009)	64 individuals with a history of migraines for at least 1 year and had completed an open trial with riboflavin (400 mg) with no concomitant drug treatment	Riboflavin (vitamin B2)	Mitochondrial haplogroups were determined by direct sequencing of the non-coding HVS-1 and HVS-2 regions of mtDNA. Patients were classified into two mtDNA haplogroups: “H” and “non-H”	Riboflavin efficacy in the treatment of migraines	Haplogroup H is a risk factor for treatment inefficacy Decrease in monthly attack frequency after riboflavin treatment was marginal in haplogroup H subjects	0.24/0.08–0.71/0.054.15/1.42–12.18/0.0001
Esteban et al. (2019)	91 patients with nAMD who received three initial monthly injections of intravitreal ranibizumab (0.5 mg/0.05 mL) followed by a flexible pro re nata period for 8 months	Ranibizumab	PCR with custom Taqman SNP genotyping assays for four mtDNA haplogroup markers (H: m.7028C>T; HV: m.14766T>C; JT: m.4216T>C; and U: m.12308A>G)	Response to intravitreal ranibizumab treatment in nAMD	After 4 months, BCVA scores were significantly higher for haplogroups HV, JT and U compared with baseline. CFT was significantly lower across all groups. At 12 months, JT BCVA scores were lower and CFT scores were higher than baseline	NR/NR/NRNR/NR/0.004
Guzmán-Fulgencio et al. (2014)	304 HIV/HCV coinfected patients who had completed a course of HCV therapy	PegIFN-α/ribavirin therapy	Genotyping was performed using the Sequenom MassARRAY platform iPLEX® Gold assay design system	SVR following pegIFN-α + ribavirin treatment	European mtDNA haplogroups were not related to HCV treatment response in HIV/HCV coinfected patients on pegIFN-α/ribavirin therapy	Multiple/Multiple/>0.05
Mittal et al. (2017)	113 European-Caucasian individuals selected from the CATIE study. Seventy four participants included after confounding factors removed	Risperidone, quetiapine or olanzapine	Mitochondrial genome was enriched by long-range PCR amplification. Products were subsequently purified and sequenced on the Illumina HiSeq 2500 platform	Antipsychotic-induced weight gain	No mtDNA SNPs were significantly associated with % weight change. No significant association between mtDNA phylogenetic groups (H-HV-V, J-T and K-U) and % weight change	NR/NR/NR
Subiabre et al. (2015)	191 warfarin-treated patients from a Chilean population, 91% of which had Amerindian background	Warfarin	Mitochondrial haplogroup characterization was performed using PCR and PCR restriction fragment length polymorphism techniques. Specific endonuclease digestion and gel visualization was used to determine the presence of 3 polymorphic sites in haplogroups A, C and D of the Amerindian population	Warfarin dosage requirements	There were no significant differences in warfarin dosage requirements among the different Amerindian haplogroups	NR/NR/0.083
Wang et al. (2019)	46 healthy peri/post-menopausal women with intact uteri and ovaries with at least one cognitive complaint and one vasomotor-related symptom	PhytoSERM (selective estrogen receptor β modulator)	Sequencing was performed by dye-terminator sequencing on a 96-capillary 3730xl DNA analyzer	Efficacy of phytoSERM for the management of menopausal symptoms	Haplogroup H had significantly deceased hot flash frequency when treated with 50 mg/day phytoSERM compared with placebo. Haplogroup H placebo subjects had lower baseline LOT scores compared with non-H haplogroups, 50 mg phytoSERM also prevented further decline in the haplogroup H	NR/NR/0.04NR/NR/0.007NR/NR/0.048

Abstraction table details the author(s), study design, drug(s) of interest, sequencing methods, outcomes, associations and statistics. BVCA, best corrected visual acuity; CATIE, clinical antipsychotic trails of intervention effectiveness; CFT, central foveal thickness; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LOT, learning over trials; mtDNA, mitochondrial DNA; nAMD, neovascular age-related macular degeneration; NR, not reported; PCR, polymerase chain reaction; pegIFN-α, pegylated-interferon-alpha; SNP, single nucleotide polymorphism; SVR, sustained virological response.